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Since the ﬁrst description of systemic
reaction induced by plant-derived food in
a patient allergic








et al. (2) suggested the designation latex-
fruit syndrome to describe this syndrome.
Turnip (Brassica rapa) belongs to the
Brassicaceae family also called Crucifer-
ae. This is known as the mustard or
cabbage family. Turnip is a root veget-
able commonly grown in temperate cli-
mates worldwide for its white, bulbous
taproot.
Zucchini (Cucurbita pepo), also known
has courgette, belongs to Cucurbitaceae
family. It is a small summer marrow or
squash, also commonly called Italian
squash. Despite being a fruit, zucchini is
considered to be a vegetable in culinary
and is traditionally picked when very
immature.
We report the case of a female patient,
42 years old, worker in the mineral
extraction industry for several years, with
signiﬁcant exposure to rubber, describing
multiple episodes of anaphylaxis. The
ﬁrst episode took place 30 min after
ingestion of chestnut when she was
25 years old. After this, she reported
other episodes after ingestion of almond
nut, hazelnut, banana, kiwi, mango,
avocado, ﬁg and tomato and recently
also with both raw and cooked zucchini
and turnip. The symptoms always inclu-
ded oral allergy syndrome, urticaria,
angioedema and glottis oedema. All the
episodes needed medical attention in the
Emergency Department. She also des-
cribes an anaphylaxis episode after
blowing latex balloons. The only medical
care with exposure to latex material was
at 23 years old when she had normal
delivery.
After the ﬁrst observation in our
Allergy Department (2005), it became
clear a clinical history suggestive of latex–
fruit syndrome.
The skin prick tests with commercial
extracts to aeroallergens, latex (ALK
Abello´, Madrid, Spain), fruits, nuts,
vegetables and legumes (Leti, Madrid,
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Figure 1. RAST inhibition with turnip and zucchini extracts. (A) RAST inhibition of latex ImmunoCAP.









Spain) revealed positive (wheal diameter
3 mm above the negative control) to kiwi,
pear, banana, watermelon, cherry, pas-
sion fruit, walnut, pistachio and latex
(wheal diameters of 4, 5, 5, 6, 5, 5, 4, 3
and 12 mm, respectively; positive control
8 mm and negative control 0 mm).
The skin prick–prick tests to several
raw foods and latex revealed positive to
latex, chestnut, walnut, pistachio nut,
blackberry, tomato, zucchini and turnip
(wheal diameter of 12, 13, 5, 4, 4, 5, 7 and
5 mm; positive control 6 mm and negat-
ive control 0 mm).
The total serum IgE level was 34 IU/l
and the serum-speciﬁc IgE to latex
3.2 KU/l (ImmunoCAPTM, Phadia,
Uppsala, Sweden). As the sensitization to
turnip and zucchini were not previously
described in the latex–vegetable–fruit
syndrome, we decided to proceed with
further investigation. The speciﬁc serum
IgE to turnip and zucchini revealed 0.64
and <0.35KU/l, respectively. Previous
incubation of serum with turnip and latex
nondiluted extracts resulted in an inhibi-
tion of 99.3% and 93%, respectively, of
turnip ImmunoCAPs reaction. Latex
ImmunoCAP reaction was inhibited with
both zucchini and turnip extract, respec-
tively (Fig. 1A). Speciﬁc IgE levels to
rHev b1 (Rk215), rHev b5 (Rk218) and
rHev b6.01 (Rk219) were 0, 0.31 and
2.9 KU/l, respectively. Inhibition study of
rHev b6.01 with nondiluted extracts of
turnip and zucchini revealed an inhibition
of 63% and 52.3%, respectively (Fig. 1B).
Despite cross-reactivity between zuc-
chini and latex had been previously des-
cribed (3) with this study, we could prove
for the ﬁrst time cross-reactivity between
turnip and latex and identify Hev b6.01,
the chitin-binding protein, as the protein
responsible in this latex–fruit syndrome.
Turnip and zucchini should be added to
the long list of plant-derived foods cross-
reactive to latex and sensitization to these
vegetables must be assessed in patients
with latex anaphylaxis.
*Servic¸o de Imunoalergologia
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Effectiveness of omalizumab
in monozygotic twin sisters
with severe allergic asthma
J. Just*, F. Sahraoui, V. Le Gros, A. Grimfeld
Between 5% and 10% of children
worldwide suﬀer from asthma (1). The
familial nature of asthma is well known;
the risk for a ﬁrst cousin of an asthmatic







higher concordance of asthma among
monozygotic (58.97%) than dizygotic
twins (23.64%) (3). We report an excep-
tional clinical situation of monozygotic
twin sisters with severe allergic asthma
where one was treated with a monoclonal
anti-IgE antibody (omalizumab), and the
other with a placebo in a randomized,
double-blind, placebo-controlled study
(4).
Premature monozygotic twin sisters
developed bronchopulmonary dysplasia
secondary to hyaline membrane disease.
Afterwards, the two sisters had similar
respiratory history; ﬁrst, asthma with
exacerbations related to viral infections
in infancy, then at the age of 6,
developing respiratory allergies to var-
ious aeroallergens with symptoms of
seasonal rhinitis and persistent atopic
dermatitis. Despite treatment with high
doses of inhaled corticosteroids in
combination with long-acting b2-mimet-
ics and delayed-release theophylline,
their asthma remained poorly con-
trolled. Repeated severe exacerbations
(>10 hospitalizations between 4 and 8)
led to several stays in the mountains for
climatic treatment. In 1998 at the age of
12, the twins were enrolled in a 32-week
randomized, double-blind, placebo-con-
trolled study (4). One received oma-
lizumab and the other a placebo. The
twin receiving omalizumab was able to
reduce her long-term treatment with
ﬂuticasone to 500 lg/day, while the
other required treatment with ﬂutica-
sone at a dose of 1250 lg/day and
regular courses of oral corticosteroids
due to persistent exacerbations. They
were both then treated with oma-
lizumab during a 6-year extension
phase. During this time, there was
clinical improvement with the absence
of hospitalizations for severe attacks,
disappearance of pollen-induced rhinitis
and improved respiratory function
(Fig. 1) under reduced long-term treat-
ment with ﬂuticasone 500 lg/day and
occasional administration of oral corti-
costeroids. The adult height of the twin
who ﬁrst received omalizumab was
159 cm compared with 156 cm for the
other.
The eﬀectiveness of omalizumab in
adolescents has previously been demon-
strated in a pooled analysis showing that
the relative risk of an adolescent aged
between 12 and <18 presenting an
asthma exacerbation when treated with
omalizumab was 0.470 compared with
the control group (95% CI: 0.318–0.695;
P ¼ 0.0002) (5). Our observation of
monozygotic twins one treated with
omalizumab and the other with a placebo
for 32 weeks, then both with omalizumab
for 6 years, and living in the same envi-
ronment, supports these ﬁndings and
suggests the eﬀectiveness of omalizumab
on a speciﬁc phenotype of severe asthma.
Omalizumab in twin
sisters.
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